Abstract:Background Circulating levels of IL-8 is related to the bone loss associated with breast cancer metastasis. Recently, we have shown that anti-citrullinated protein antibodies (ACPA) can induce osteoclastogenesis. Objectives We aimed to investigate the role of IL-8 and its receptors in mediating osteoclastogenesis in presence or absence of ACPAs Methods IL-8 levels was measured by ELISA in serum of risk RA patients and synovial fluid samples of RA patients. CD14 positive monocytes were used to generate osteoclasts with M-CSF and RANKL. Inhibition of IL-8 and its receptor were tested with IL-8 neutralizing antibody or small molecule CXCR1/2 anta-agonist (Reparixin and SCH-527123) on osteoclasts (OC) in the presence or absence of ACPA. The number of the OC9s were counted in light microscope after TRAP staining. Cell counting kit 8 (CCK8) assay was performed to detect cytotoxicity. CXCR1 and CXCR2 expression was analyzed using flow cytometry and immunohistochemistry during different days of osteoclasts maturation. Results Increased IL-8 levels were observed in the serum of ACPA positive at risk RA healthy individuals and in synovial fluid of established ACPA positive RA patients. Exogenous IL-8 dose dependently increased OC numbers in presence of RANKL. IL-8 neutralizing antibody inhibited the OC numbers even in the presence of ACPA. Reparixin and SCH-527123 significantly inhibited RANKL mediated osteoclastogenesis at 100 μM concentration. No cytotoxicity of the drugs were detected with CCK8 assay. Immunohistochemistry staining confirmed the CXCR1/2 expression on OC precursors. We found high expression of IL-8 using immunohistochemistry on the inflammed RA synovium.We observed CXCR1 and CXCR2 expression with flow cytometry in the OC precursors at day 0 and in presence of RANKL the expression was completely lost at day 1 and it reappeared at day 4. Conclusions Our data provides insights in to the importance of IL-8 autocrine loop in RANKL and ACPA mediated OC development. IL-8 receptor blockade might be a novel way of targeting bone loss in RA. Disclosure of Interest None declared

Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis

Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss

Antibodies to Citrullinated Proteins: Molecular Interactions and Arthritogenicity

Anticitrullinated Protein Antibodies Facilitate Migration of Synovial Tissue-Derived Fibroblasts.

Autoantibodies to Citrullinated Proteins Induce Joint Pain Independent of Inflammation Via A Chemokine-Dependent Mechanism

Anti-citrullinated Protein Antibodies Cause Arthritis by Cross-Reactivity to Joint Cartilage.

Autoantibodies to Citrullinated Proteins May Induce Joint Pain Independent of Inflammation

ACPA Mediates the Interplay Between Innate and Adaptive Immunity in Rheumatoid Arthritis.

Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis

Structural Basis of Cross‐Reactivity of Anti–Citrullinated Protein Antibodies

The role of anti-citrullinated protein antibody in pathogenesis of RA

A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis

The Structure, Specificity and Function of Anti-Citrullinated Protein Antibodies

Affinity Purified Anti-Citrullinated Protein/peptide Antibodies Target Antigens Expressed in the Rheumatoid Joint.

Aberrant Activation of Immune and Non-Immune Cells Contributes to Joint Inflammation and Bone Degradation in Rheumatoid Arthritis

Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis

In Early Rheumatoid Arthritis, Anticitrullinated Peptide Antibodies Associate with Low Number of Affected Joints and Rheumatoid Factor Associates with Systemic Inflammation.

Role Of Il-8 And Its Receptor In Anti-Citrullinated Protein Antibody Mediated Osteoclastogenesis In Ra

Bridging autoantibodies and arthritis: the role of Fc receptors

Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?

Citrullinated Peptide And Its Relevance To Rheumatoid Arthritis: An Update